Ertugliflozin

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 346 publications

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Journal: Pulmonology

Published: March 10, 2026

Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models.

Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 02, 2025

Noninsulin drugs for type 2 diabetes.

Noninsulin drugs for type 2 diabetes.

Journal: The Medical letter on drugs and therapeutics

Published: November 19, 2025

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Journal: The Medical letter on drugs and therapeutics

Published: November 19, 2025

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis.

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis.

Journal: Clinical nephrology

Published: November 14, 2025

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Cureus

Published: November 09, 2025

Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.

Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: October 13, 2025

Impact of Ertugliflozin on Cardiac Structure and Function in Patients with ICDs/CRT-Ds Assessed by Echocardiography: A Post Hoc Sub-Analysis of the ERASe Trial.

Impact of Ertugliflozin on Cardiac Structure and Function in Patients with ICDs/CRT-Ds Assessed by Echocardiography: A Post Hoc Sub-Analysis of the ERASe Trial.

Journal: Journal of clinical medicine

Published: October 10, 2025

Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights.

Attenuation of cerebral ischemia-reperfusion induced neurotoxicity by telmisartan, ertugliflozin, and omaveloxolone through Nrf2/HO-1 pathway modulation: In vivo and in silico insights.

Journal: Toxicology reports

Published: October 05, 2025

Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin.

Multiscale computational analysis reveals enhanced allosteric modulation of Nav1.5 by dual binding of dapagliflozin and ertugliflozin.

Journal: Scientific reports

Published: September 12, 2025

Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR T + Itpr3tf/J mouse model of autism.

Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR T + Itpr3tf/J mouse model of autism.

Journal: Brain communications

Published: September 03, 2025

Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.

Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.

Journal: Journal of the American College of Cardiology

Published: August 27, 2025

Showing 1-12 of 346

Last Updated: 04/28/2026